var data={"title":"Lorcaserin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lorcaserin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/513713?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lorcaserin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lorcaserin: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20607192\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Belviq;</li>\n      <li>Belviq XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14593997\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anorexiant;</li>\n      <li>\n        Serotonin 5-HT<sub>2C</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668900\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Weight management:</b> Oral: <b>Note:</b> Evaluate response by week 12; if patient has not lost &ge;5% of baseline body weight, discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: 20 mg once daily (maximum: 20 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 10 mg twice daily (maximum: 20 mg/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668904\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668901\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (CrCl &gt;50 mL/minute): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (CrCl 30 to 50 mL/minute): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution; serum concentrations and half-life of major metabolites are increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (CrCl &lt;30 mL/minute): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD: Use is not recommended; hemodialysis does not remove lorcaserin or M1 metabolite</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668902\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution (has not been studied); undergoes extensive hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20712959\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Belviq: 10 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Belviq XR: 20 mg [contains fd&amp;c yellow #6 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668754\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324281\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668905\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or without food. Swallow extended-release tablets whole; do not chew, crushed, or divide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14584097\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Weight management:</b> Chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity, in adults  with either an initial body mass index (BMI) of &ge;30 kg/m<sup>2</sup> <b>or</b> an initial BMI of &ge;27 kg/m<sup>2</sup> and at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668752\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lorcaserin hydrochloride may be confused with loratadine hydrochloride (Claritin) and losartan (Cozaar)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lorcaserin may be confused with Lotensin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668859\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (15% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (diabetic patients 29%; symptomatic 7%; severe: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic: Abnormal lymphocytes (below lower limit of normal after &ge;1 year, 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (14%), nasopharyngitis (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (5%), peripheral edema (5%), decreased heart rate (less than 50 bpm: 4% to 5%), acquired valvular heart disease (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7% to 9%), fatigue (7%), anxiety (4%), insomnia (4%), depression (3%), stress (3%), cognitive dysfunction (2%), psychiatric disturbance (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum prolactin (7%; 2 x ULN: 2%; 5 x ULN: &lt;1%), exacerbation of diabetes mellitus (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (8% to 9%), diarrhea (7%), constipation (6%), xerostomia (5%), vomiting (4%), gastroenteritis (3%), toothache (3%), decreased appetite (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic: Decreased hemoglobin (10%), decreased neutrophils (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Seasonal allergy (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (5%), musculoskeletal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ocular: Eye disease (5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4% to 8%), oropharyngeal pain (4%), sinus congestion (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction, serotonin syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668758\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lorcaserin or any component of the formulation; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668759\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause confusion, somnolence, fatigue, and cognitive impairment (difficulty with concentration/attention/memory); patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematological effects: Leukopenia, lymphopenia, neutropenia, anemia, and/or decreases in hematocrit and hemoglobin have been observed. Consider monitoring CBC periodically during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: May occur; in general, increases are moderate (&le;2 x ULN), although prolactin elevations (5 x ULN) have been reported rarely. Obtain prolactin levels if signs or symptoms of hyperprolactinemia occur (eg, galactorrhea, gynecomastia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: May occur with use; men with erections &gt;4 hours should immediately discontinue lorcaserin and seek emergency medical attention to avoid irreversible damage to erectile tissue. Use with caution in men with conditions that increase the risk for priapism (eg, sickle cell anemia, multiple myeloma, leukemia) or men with anatomical penis deformities (eg, angulation, cavernosal fibrosis, Peyronie disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Primary pulmonary hypertension (PPH): Has been reported in patients receiving other centrally acting, serotonergic weight loss agents. Available data from clinical trials are inadequate to determine if lorcaserin increases the risk for pulmonary hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Euphoria, hallucinations, and dissociation have been observed with lorcaserin at supratherapeutic doses. Monitor patients closely during use for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior; discontinue for suicidal thoughts or behaviors; discontinue lorcaserin in patients who experience suicidal thoughts or behaviors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome (SS)/neuroleptic malignant syndrome (NMS)-like reactions: SS and NMS-like reactions have occurred with serotonergic agents such as lorcaserin, particularly when used in combination with other serotonergic agents (eg, triptans, SNRIs, SSRIs, TCAs, bupropion, St John&rsquo;s wort, tryptophan), agents that impair metabolism of serotonin (eg, MAO inhibitors, dextromethorphan, tramadol, lithium), or antidopaminergic agents (eg, antipsychotics). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) may be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valvular heart disease: Cardiac valvular disease has been associated with the use of agents exhibiting potent 5-HT<sub>2B</sub> agonist activity (eg, cabergoline, fenfluramine [not currently on the US market], dexfenfluramine [not currently on the US market]). Cardiac valvular disease is believed to result from activation of 5-HT<sub>2B</sub> receptors in interstitial cardiac cells. Lorcaserin has greater affinity for 5-HT<sub>2C</sub> receptors compared to 5-HT<sub>2B</sub> receptors (at therapeutic doses). However, a slight increase in incidence of regurgitant cardiac valve disease (mitral and/or aortic) has been observed with lorcaserin compared to placebo in some clinical trials (pooled RR: 1.16; 95% CI: 0.81 to 1.67). The incidence observed in both groups was low, making it difficult to ascertain the risk of valvular disease with lorcaserin therapy based on available data. Evaluate patients if signs/symptoms of valvular heart disease (eg, dyspnea, dependent edema, heart failure, new onset cardiac murmur) arise during therapy; consider discontinuing therapy if present. Use has not been studied in patients with hemodynamically-significant valvular heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with bradycardia or heart block (second or third degree); bradycardia has been observed rarely with use. Use with caution in patients with heart failure (has not been studied); data suggests that 5HT<sub>2B</sub> receptors may be overexpressed in heart failure which could potentially increase the risk of valvular heart disease developing from use. In a scientific statement from the American Heart Association, lorcaserin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: major) (AHA [Page 2016]). Effect of lorcaserin on cardiovascular morbidity and mortality has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with type 2 diabetes mellitus; weight loss from therapy may result in decreased requirements of antidiabetic agents and an increased risk of hypoglycemia; monitor blood glucose. Hypoglycemia has been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (has not been studied). Lorcaserin undergoes extensive hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Serum concentrations and principal metabolite (M1 and M5) half-lives are increased in renal impairment. Use is not recommended in patients with severe impairment or end stage renal disease. Use with caution in patients with moderate renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: Incidences of euphoria and hallucinations were low (&lt;1%) in clinical trials of obese patients with durations up to 104 weeks; however, in abuse potential studies of recreational drug abusers and in short term studies of healthy patients using supratherapeutic doses, the incidences of hallucinations and euphoria were higher (&gt;10%). May produce psychic dependence. Physical dependence or a withdrawal syndrome has not been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Pharmacotherapy for weight loss should be used in conjunction with a comprehensive weight management program including diet and exercise. Discontinue if significant weight loss has not occurred (ie, &lt;5% within the first 12 weeks of treatment). The safety and efficacy of coadministration with other products intended for weight loss have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896883\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896881\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85674&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the serotonergic effect of Lorcaserin. This could result in serotonin syndrome. Management: Seek alternatives to this combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Lorcaserin may enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: Lorcaserin may enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668755\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668756\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Due to the fact that weight loss during pregnancy offers no clinical benefit, lorcaserin is contraindicated in pregnancy. Obese and overweight women should be encouraged to participate in weight reduction programs prior to attempting pregnancy; weight gain during pregnancy should be determined by their prepregnancy BMI and current guidelines (ADA 2009; IOM 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15669542\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Lorcaserin may alter maternal serum prolactin concentrations. It is not known if lorcaserin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer. Weight-loss therapy is generally not recommended for lactating women. Weight-loss programs which include physical activity and nutrition components should be discussed at the 6-week postpartum visit (ADA 2009; IOM 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668919\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Weight, waist circumference; CBC (periodically during use); blood glucose (in diabetics); prolactin levels (if galactorrhea, gynecomastia or other signs/symptoms of hyperprolactinemia arise); monitor for depression and/or suicidal thoughts/behavior; signs/symptoms of SS/NMS-like reaction; signs/symptoms of valvular heart disease (dyspnea, dependent edema)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668881\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lorcaserin is believed to activate serotonin 5-HT<sub>2C</sub> receptors, which stimulate pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, leading to increased alpha-melanocortin stimulating hormone release at melanocortin-4 receptors and resulting in satiety and decreased food intake. At recommended doses, lorcaserin has greater affinity for 5-HT<sub>2C</sub> receptors compared to other 5-HT receptor subtypes (including 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>), the 5-HT receptor transporter, and 5-HT reuptake sites (Hurren, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15668883\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes to the CNS and cerebrospinal fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~70% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive hepatic metabolism, via multiple enzymatic pathways, producing two major metabolites (inactive), lorcaserin sulfamate (M1) and N-carbamoyl glucuronide lorcaserin (M5), as well as minor metabolites (glucuronide and sulfate conjugates)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~11 hours (immediate-release); ~12 hours (extended-release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1.5 to 2 hours (immediate release); 10 hours (extended release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (92%, as metabolites); feces (2%, as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21663590\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Belviq XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $317.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Belviq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $317.93</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939747\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Belviq (BB, IL, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Dietetic Association; American Society of Nutrition, Siega-Riz AM, et al, &quot;Position of the American Dietetic Association and American Society for Nutrition: Obesity, Reproduction, and Pregnancy Outcomes,&quot; <i>J Am Diet Assoc</i>, 2009, 109(5):918-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/19412993/pubmed\" target=\"_blank\" id=\"19412993\">19412993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belviq (lorcaserin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belviq XR (lorcaserin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. <i>J Clin Endocrinol Metab.</i> 2011;96(10):3067-3077.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/21795446/pubmed\" target=\"_blank\" id=\"21795446\">21795446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurren KM and Berlie HD, &ldquo;Lorcaserin: An Investigational Serotonin 2C Agonist for Weight Loss,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(21):2029-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/22011982/pubmed\" target=\"_blank\" id=\"22011982\">22011982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine) and NRC (National Research Council), &quot;Weight Gain During Pregnancy: Reexamining the Guidelines,&quot; Washington, DC: The National Academies Press, 2009. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/20669500/pubmed\" target=\"_blank\" id=\"20669500\">20669500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin CK, Redman LM, Zhang J, et al, &ldquo;Lorcaserin, a 5-HT(2C) Receptor Agonist, Reduces Body Weight By Decreasing Energy Intake Without Influencing Energy Expenditure,&rdquo; <i>J Clin Endocrinol Metab</i>, 2011, 96(3):837-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/21190985/pubmed\" target=\"_blank\" id=\"21190985\">21190985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Neil PM, Smith SR, Weissman NJ, et al, &ldquo;Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study,&rdquo; <i>Obesity</i>, 2012, 20(7):1426-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/22421927/pubmed\" target=\"_blank\" id=\"22421927\">22421927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SR, Weissman NJ, Anderson CM, et al, &ldquo;Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management,&rdquo; <i>N Engl J Med</i>, 2010, 363(3):245-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorcaserin-drug-information/abstract-text/20647200/pubmed\" target=\"_blank\" id=\"20647200\">20647200</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85674 Version 96.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20607192\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14593997\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15668900\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15668904\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15668901\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15668902\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20712959\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15668754\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F20324281\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15668905\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14584097\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15668752\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15668859\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15668758\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15668759\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15896883\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15896881\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F15668755\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15668756\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15669542\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15668919\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15668881\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15668883\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21663590\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939747\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85674|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lorcaserin-patient-drug-information\" class=\"drug drug_patient\">Lorcaserin: Patient drug information \t</a></li></ul></div></div>","javascript":null}